A combination of empagliflozin and pirfenidone significantly improved heart function and reduced scarring in rats with heart failure, working better together than either drug alone. According to Gram Research analysis, the dual therapy restored the heart’s ability to pump and relax by blocking multiple disease pathways simultaneously, suggesting that targeting multiple problems at once may be more effective than single-drug approaches for this common type of heart failure.
Researchers tested a combination of two medications on rats with a common type of heart failure called HFpEF, which affects more than half of heart failure patients. According to Gram Research analysis, when empagliflozin and pirfenidone were given together, they worked better than either drug alone at improving how the heart pumped blood and reducing scarring in heart tissue. The combination appeared to work by targeting multiple problems in the heart at the same time. While these results are promising, the study was done in rats, so more research in humans is needed before doctors can prescribe this combination to patients.
Key Statistics
A 2026 preclinical study of 16 rats per group found that combined empagliflozin and pirfenidone therapy significantly improved diastolic function, ejection fraction, and fractional shortening compared to either drug alone or no treatment (p < 0.05).
Research published in Frontiers in Pharmacology showed that dual therapy with empagliflozin and pirfenidone reduced cardiomyocyte hypertrophy and collagen deposition in heart tissue, particularly in the endocardium, more effectively than monotherapy in a rat model of HFpEF.
A 2026 animal study demonstrated that the combination of empagliflozin and pirfenidone achieved compartmentalized synergy by blocking PKC/NF-κB inflammatory pathways and TGF-β-driven fibrosis, restoring both diastolic and systolic cardiac function.
Gene sequencing analysis in the study revealed that dual therapy activated protective protein kinase C-related signaling networks while simultaneously suppressing fibrosis-promoting pathways, explaining the superior efficacy of the combination approach.
The Quick Take
- What they studied: Whether combining two heart medications (empagliflozin and pirfenidone) works better than using just one medication for treating a type of heart failure where the heart doesn’t pump out enough blood.
- Who participated: The study used 16 rats per group that were given a disease to mimic heart failure in humans. The rats were treated for 4 weeks with different combinations of medications.
- Key finding: Rats receiving both medications together showed significantly better heart function and less scarring compared to rats getting only one medication or no treatment (p < 0.05, meaning the results were statistically significant).
- What it means for you: This research suggests that combining medications that work in different ways might be more effective for treating certain types of heart failure. However, this was tested only in rats, so human studies are needed before this approach can be used in patients.
The Research Details
Scientists created heart failure in rats using two methods: a chemical that damages blood vessel function and a high-fat diet. After 5 weeks, the rats had heart problems similar to a common human condition called HFpEF (heart failure with preserved ejection fraction). The researchers then divided the rats into groups and gave them different treatments for 4 weeks: empagliflozin alone, pirfenidone alone, both medications together, or no treatment.
To measure whether the treatments worked, the scientists used ultrasound to look at the heart, examined heart tissue under a microscope, tested how far the rats could run, and analyzed the genes being turned on and off in heart cells. This multi-method approach helped them understand not just whether the drugs worked, but also how they worked at the cellular level.
The researchers used a special statistical method called Bliss independence analysis to determine whether the two drugs worked better together than expected if they just added their effects together.
Heart failure is a major health problem, and the type studied here (HFpEF) is especially difficult to treat because it involves multiple problems happening at the same time in the heart. Single medications often don’t work well enough because they only address one problem. By testing a combination approach that targets different pathways, this research explores whether hitting multiple targets simultaneously could be more effective.
This study was conducted in a controlled laboratory setting with consistent rat strains and carefully measured outcomes. The use of multiple measurement methods (imaging, tissue analysis, genetic testing) strengthens the findings. However, the main limitation is that results in rats don’t always translate to humans. The sample size of 16 rats per group is typical for preclinical research but relatively small. The study was published in a peer-reviewed journal, which means other experts reviewed the work before publication.
What the Results Show
The combination of empagliflozin and pirfenidone produced the best results. Rats receiving both drugs showed significantly improved heart function measurements compared to control rats and rats receiving only one drug. Specifically, the combination improved how well the heart relaxed between beats (diastolic function) and how much blood it pumped out (ejection fraction and fractional shortening).
When researchers looked at heart tissue under a microscope, they found that the combination therapy reduced two major problems: the heart muscle cells were smaller (less hypertrophy) and there was less scarring (fibrosis), particularly in the inner lining of the heart. These structural improvements matched the functional improvements seen on the heart ultrasounds.
At the molecular level, the researchers discovered that the combination worked by blocking inflammatory pathways and reducing fibrosis-promoting signals in the heart. Specifically, the drugs appeared to block a pathway called PKC/NF-κB and reduced signals from TGF-β, a protein that promotes scarring. This explains why the combination was more effective than either drug alone.
While the combination therapy showed the best results, empagliflozin alone and pirfenidone alone each provided some benefit compared to no treatment. However, the improvements were less dramatic than with the combination. The study also found that the combination therapy’s benefits were concentrated in the heart muscle itself rather than being a simple addition of each drug’s effects on the whole body’s blood pressure and fluid balance.
Previous research has shown that empagliflozin (an SGLT2 inhibitor) can help reduce hospitalizations in HFpEF patients, and pirfenidone is known to reduce scarring in other heart and lung conditions. This study is novel because it’s the first to test whether combining these two drugs produces better results than either alone in an HFpEF model. The finding of compartmentalized synergy (where the combination works especially well in the heart tissue itself) is a new insight that wasn’t previously demonstrated.
The most important limitation is that this research was conducted in rats, not humans. Rat physiology differs from human physiology, and results that look promising in animals don’t always work the same way in people. The study used only 16 rats per group, which is a small sample size. The treatment period was relatively short (4 weeks), so it’s unclear whether benefits would continue or change over longer periods. The study didn’t test different doses or timing of medications, so the optimal way to use this combination in humans remains unknown. Finally, this was a controlled laboratory study, so real-world factors like patient compliance and individual variations weren’t considered.
The Bottom Line
Based on this preclinical research, the combination of empagliflozin and pirfenidone shows promise for treating HFpEF by working on multiple disease mechanisms simultaneously. However, confidence in recommending this approach is currently low because the evidence comes only from animal studies. Human clinical trials would be needed before this combination could be prescribed to patients. If such trials are conducted and show similar benefits, this approach could potentially become a treatment option for HFpEF patients in the future.
This research is most relevant to cardiologists and researchers studying heart failure, particularly those interested in HFpEF. Patients with HFpEF should be aware of this emerging research but should not expect this combination to be available soon. Pharmaceutical companies developing heart failure treatments should find this work interesting as it demonstrates a potential new therapeutic approach. Healthcare policymakers should note that this research supports the need for more funding of combination therapy research.
Since this is preclinical research, there is no immediate timeline for patient benefit. Typically, promising animal research takes 5-10 years to progress through human clinical trials before becoming available as a treatment. If clinical trials are initiated soon, the earliest this combination might become available to patients would be 7-10 years from now.
Frequently Asked Questions
Can I take empagliflozin and pirfenidone together for heart failure?
This combination has only been tested in rats so far, not in human patients. While results are promising, you should not take this combination without a doctor’s prescription and supervision. Talk to your cardiologist about whether either medication individually is appropriate for your condition.
What is HFpEF and why is it hard to treat?
HFpEF (heart failure with preserved ejection fraction) is a type of heart failure where the heart doesn’t relax properly between beats, even though it pumps out a normal amount of blood. It’s difficult to treat because multiple problems occur simultaneously—inflammation, scarring, and metabolic stress—so single medications often don’t work well enough.
How long until this drug combination is available for patients?
This research is in early stages. Typically, promising animal studies take 5-10 years to progress through human clinical trials. If trials begin soon, this combination might become available to patients in 7-10 years, though there’s no guarantee it will work the same way in humans.
Why did the combination work better than single drugs in this study?
The combination targeted multiple disease pathways simultaneously. Empagliflozin addresses metabolic stress, while pirfenidone reduces scarring. Together, they blocked inflammation and fibrosis-promoting signals more effectively than either drug alone could achieve.
Should I expect this treatment to work the same in humans as it did in rats?
Not necessarily. While rat studies provide valuable proof of concept, human physiology is more complex. Results in animals don’t always translate directly to humans. Human clinical trials would be needed to confirm safety and effectiveness before this combination could be prescribed to patients.
Want to Apply This Research?
- Users with heart failure could track their exercise tolerance (how far they can walk or how long they can exercise before getting tired) weekly, as this was a key measure of improvement in the study. They could also monitor shortness of breath during daily activities on a scale of 1-10.
- While awaiting human trials, users could discuss with their cardiologist whether they’re currently taking empagliflozin or similar medications. They could also track lifestyle factors that support heart health, such as diet quality, sodium intake, and physical activity, which complement any medical treatment.
- Long-term tracking should focus on heart-related symptoms (shortness of breath, fatigue, swelling) and exercise capacity. Users should maintain regular contact with their cardiologist and report any changes in symptoms. As this research progresses toward human trials, users interested in this approach should discuss clinical trial participation with their healthcare provider.
This research was conducted in rats and has not been tested in humans. The findings are preliminary and do not constitute medical advice. Individuals with heart failure should not attempt to use empagliflozin and pirfenidone together without explicit prescription and supervision from a qualified cardiologist. This article is for educational purposes only and should not replace professional medical consultation. Always consult with your healthcare provider before starting, stopping, or changing any medication regimen.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.